Publication: Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults
Issued Date
2006-02-27
Resource Type
ISSN
0264410X
Other identifier(s)
2-s2.0-32344443602
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Vaccine. Vol.24, No.9 (2006), 1238-1241
Suggested Citation
Scott Kitchener, Michael Nissen, Peter Nasveld, Remi Forrat, Sutee Yoksan, Jean Lang, Jean François Saluzzo Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine. Vol.24, No.9 (2006), 1238-1241. doi:10.1016/j.vaccine.2005.09.029 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/23078
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults
Other Contributor(s)
Abstract
We conducted a Phase 1b study to evaluate the immunogenicity and safety of two live attenuated tetravalent dengue vaccines in healthy adult volunteers. After one injection, all subjects reported systemic reactions consistent with a mild dengue-like syndrome. Seven volunteers developed dengue 3 viraemia after vaccination. All subjects developed a neutralizing antibody response against serotype 3 with partial response against other serotypes. The trial was stopped early (after 10 subjects enrolled) due to formulation issues, which were related to the dengue 3 vaccine component. Managing viral interference and balancing attenuation to produce acceptable tetravalent immunogenicity with minimal reactogenicity may be a recurring problem for future multivalent live vaccines. © 2005 Elsevier Ltd. All rights reserved.